Much of the variation in inherited risk of glioma is likely to be explained by combinations of common low risk variants. The established relationship between glioma risk and exposure to ionising radiation led us to examine whether variants in the DNA repair genes contribute to disease susceptibility. We evaluated 1,127 haplotype-tagging single nucleotide polymorphisms (SNPs) supplemented with 388 putative functional SNPs to capture most of the common variation in 136 DNA repair genes, in five unique case-control series from four different countries (1,013 cases, 1,016 controls). We identified 16 SNPs associated with glioma risk at the 1% significance level. The highest association observed across the five independent case-control datasets involved rs243356, which maps to intron 3 of CHAF1A (trend odds ratio, 1.32; 95% confidence interval, 1.14-1.54; P = 0.0002; false positive report probability = 0.055, based on a prior probability of 0.01). Our results provide additional support for the hypothesis that low penetrance variants contribute to the risk of developing glioma and suggest that a genetic variant located in or around the CHAF1A gene contributes to disease risk.
INTRODUCTION
Gliomas account for ~80% of primary malignant brain tumours and ~21,000 cases are diagnosed each year in the US (1) . Evidence for an inherited predisposition to risk of developing glioma is provided by the single gene disorders neurofibromatosis type 1 and 2, tuberous sclerosis, retinoblastoma, Li-Fraumeni syndrome, and Turcot's syndrome (1, 2) . While these syndromes confer substantial risk of developing glioma, they are rare and collectively only make a minor contribution to the 2 to 3-fold increased risk seen in first-degree relatives of patients (1, 3) . To date, few environmental risk factors have unambiguously been shown to influence glioma risk, and it is likely that the residual familial risk is mediated by as yet unidentified genetic factors including low risk variants, some of which may be common and therefore detectable through association analyses.
Inherited dysfunction of DNA repair is the underlying basis of genetic susceptibility to many cancers. This, coupled with the established relationship between glioma risk and exposure to ionising radiation (4), provides a strong rationale to explore whether variation in the DNA repair genes contributes to disease susceptibility.
Here we report an analysis of the relationship between common variation in 136 DNA repair genes and the risk of developing glioma. We based our analysis on five case-control series established in association with the Interphone Study (5). In addition to assaying 1,127 tagging single nucleotide polymorphisms (SNPs) selected to capture most of the common variation in the DNA repair genes, we also genotyped 388 putative functional SNPs, including 69 nonsynonymous coding SNPs, that have the potential to impact directly on the function of expressed proteins. The observed number of SNPs with significant deviation from HWE (P < 0.05) was not significantly more than the expected number in the control population from any of the five study centres. The estimate of the stratification parameter of the genomic control method was close to unity in all of five case-control datasets with λˆvalues of: UK-North, 1.06 (95% confidence interval [CI]: 0.93-1.20); UK-Southeast, 0.75 (95% CI: 0.68-0.86); Sweden, 1.12 (95% CI: 1.00-1.22); Finland, 0.93 (95% CI: 0.82-1.05), Denmark, 1.10 (95% CI: 0.97-1.22). These data provide no evidence of population stratification as a cause of false positive results. Furthermore, no evidence was found for differences in genotype frequencies of SNPs between male and female controls as a source of potential confounding in subsequent analyses. There was slight evidence of over-inflation of the test statistics as assessed by a quantile-quantile (Q-Q) plot of the CochranArmitage test statistics adjusted by logistic regression for study centre, age, and sex (Figure 1 ), but this was more pronounced among the smaller test statistics and does not substantially change the result of this study.
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Seventy-eight of the 1,458 SNPs were significantly associated with the risk of glioma at the 5% level (Supplementary Table 1 ) and 16 at the 1% level (Table 1) . Adjusting for age and sex did not substantially affect study findings (data not shown).
The most highly associated SNP, rs243356, which maps to intron 3 of CHAF1A, was significant at the 0.1% level (P = 0.0002). This association was consistent across the five casescontrol series with little evidence of heterogeneity (Q = 8.4, 4 df; P = 0.08). The associated false positive report probability (FPRP) was 0.055, well below the 0.200 threshold for false-positivity Of the seven SNPs we genotyped that map to CHAF1A, three in addition to rs243356 were significant at the 1% level: rs243341 and rs105038, which are in tight linkage disequilibrium (LD) and map to introns 1 and 3, and rs2992, which maps to the 3' UTR and a putative exonic sequence enhancer (Figure 2 ). The risk allele for rs243356 is found in only 1 of the 6 haplotypes predicted in the LD block defined by these 7 SNPs, and none of the haplotypes defined by these SNPs is more strongly associated with risk of glioma than the SNP rs243356 on its own.
Other associations identified included two SNPs mapping to ERCC1, three SNPs mapping to RPA3 and two SNPs mapping to DCLRE1B. Single SNP associations were identified for NEIL3, TP53, POLD1, ATR and MSH5 (Table 1) .
Interactions between the 16 SNPs that showed some association with risk (P < 0.01) were examined by fitting full logistic regression models for each pair, generating 120 models, and comparing these with the main effects model. Five pairs of SNPs showed nominally significant interaction at the 5% level, but the strongest interaction, between rs6947203 and rs4140805 (P = 0.02), was non-significant after correction for multiple testing.
DISCUSSION
Our study has systematically evaluated the association of DNA repair genes with glioma risk, on the basis of a priori evidence implicating such variation in cancer risk. While gliomas are the most frequent primary brain tumour, they are relatively rare and most previous association studies have been conducted on small numbers of cases and controls, thereby having modest power to identify associations. Moreover most studies to date have only evaluated a very restricted set of loci. A major strength of our study is that it has been based on several casecontrol series collected in the same consistent fashion to generate a uniquely large dataset. Rather than rely on the standard P value criterion of 0.05 to define statistical significance we have computed associated FPRP values for associations identified. This metric depends not only on the observed P value, but also on the prior probability (i.e. strength of belief) that the association between the variant and the disease is real, and on the statistical power of the study. While this approach is in essence Bayesian, it retains the principle of distinguishing those observations that are noteworthy from those that are likely to be simply a consequence of chance (type I errors).
Use of the FPRP therefore avoids correcting for multiple testing using a simple Bonferroni procedure which is inherently conservative especially when SNPs are correlated, as is the case in our study when many polymorphisms tag the same region. Furthermore, the approach does not require specification of a prior probability distribution for the OR, which can be burdensome. One limitation to the FPRP approach, however, is assigning a prior probability. On the basis of the biological plausibility of candidate genes selected for evaluation, we have imposed a low prior in keeping with the work of others and to be relatively conservative (16).
Our strongest finding was the association of risk with rs243356, which maps to the gene CHAF1A. Although we cannot exclude the possibility that the association was attributable to at Pennsylvania State University on February 28, 2013 http://hmg.oxfordjournals.org/ Downloaded from chance, the association had a low FPRP, providing some measure of robustness to our observation.
CHAF1A is a part of the chromatin assembly factor 1 (CAF-1) complex, which is thought to mediate chromatin assembly in DNA replication and repair by assembling histones into nucleosomes. Although the biological function of CAF-1 has yet to be fully elucidated, several studies have already linked this complex to cancer biology. Expression of CAF-1 has been associated with cell proliferation in breast cancer (18), and CAF-1-mediated deregulation of cell proliferation and DNA repair has been linked to the aggressive behaviour of squamous carcinoma (19). CAF-1 also interacts with the gene product associated with the recessively inherited Bloom's syndrome (MIM 210900) which is characterised by genomic instability and cancer susceptibility (20). Therefore, while the functional role of CHAF1A in primary brain tumours is currently unsubstantiated, a biological relevance in development of glioma is highly plausible.
Haplotype analysis was not informative, as it did not suggest that glioma risk was substantially elevated among individuals with specific haplotypes, compared to individuals with single SNP risk alleles. It is however unlikely that rs243356 is a causal factor itself, and more probable that the association identified is a consequence of LD with a causal variant. On the basis that we failed to detect an association with any of the common nsSNPs of CHAF1A, it is likely that the functional effects are mediated through LD with sequence changes within the promoter or enhancer elements of the gene influencing differential expression of CHAF1A. Alternatively, there is the possibility that the rs243356 tags a causative variant located outside of the CHAF1A locus.
Variants in a number of the other genes we identified represent plausible candidates for determining glioma risk on the basis of their biology. These include ATR (MIM 601215) and RPA3 (MIM 179837), both of which participate in cell cycle checkpoint signalling pathways required for cellular response to DNA damage and for genome stability.
Our study is the first to evaluate the risk of glioma associated with a comprehensive set of DNA repair genes. Our analysis provides evidence that common low risk variants contribute to risk of developing glioma and implicates variants of CHAF1A as risk factors. As with all association studies however, it is highly desirable that our findings are replicated in independent case-control series. Moreover, for some datasets it may prove highly advantageous to conduct analyses of the interaction of genotype with environmental risk factors, notably radiation exposure, where such information has robustly been collected.
MATERIALS AND METHODS

Study subjects
The study was based on five case-control studies that contributed to the Interphone Study selected from general practitioners' practice lists, individually matched to cases by age and sex in the Northern UK, and frequency matched on sex, age, and region in the Southeastern UK.
Controls had no history of a cerebral tumour.
In Sweden, the Southeast region of the UK (UK-Southeast), the Northern UK (UKNorth), and Denmark, a blood sample was drawn from cases and controls who participated in the interview and agreed to provide a blood sample. Finnish investigators did not attempt to collect blood from all interviewed participants; rather, they drew blood from a convenience sample, of predetermined size, from patients in three hospitals and controls living in the area served by these hospitals.
Samples and clinico-pathological information from participants were obtained with informed consent and ethical review board approval in accordance with the tenets of the Declaration of Helsinki.
To minimize population stratification, cases and controls with ethnic origin other than the country of recruitment were excluded from the present study. All remaining cases with sufficient DNA quantity and quality were included. Controls genotyped met the same requirements for DNA quantity and quality as cases, and were randomly frequency matched by gender to eligible cases for each study centre. The number, sex and age of cases and controls in each of the five studies analysed in the current study were: UK-North: 370 cases (230 male, 140 female; mean age at diagnosis 49 years; SD ± 12) and 369 controls (231 male, 138 female; mean age 51 years; SD ± 11); UK-Southeast: 211 cases (140 male, 71 female; mean age at diagnosis 42 years; SD ± 11) and 214 controls (142 male, 72 female; mean age 47 years; SD ± 9); Sweden: 197 cases (121 male, 76 female; mean age at diagnosis 50 years; SD ± 13) and 197 controls (121 male, 76 female; mean age 52 years; SD ± 12); Denmark: 128 cases (71 male, 57 female; mean age at diagnosis 48 years; SD ± 12) and 131 controls (74 male, 57 female; mean age 51 years; SD ± 12); Finland: 99 cases (56 male, 43 female; mean age at diagnosis 48 years; SD ± 12) and 100 controls (37 male, 63 female; mean age 53 years; SD ± 12) .
SNP genotyping and data manipulation
DNA was extracted from samples using conventional methodologies and quantified using PicoGreen (Invitrogen Corp., Carlsbad, CA, USA). Genotyping of samples was performed using customized Illumina GoldenGate Arrays (Illumina Inc., San Diego, CA, USA). DNA samples with GenCall scores < 0.25 at any locus were considered "no calls". A DNA sample was deemed to have failed if it generated genotypes at fewer than 80% of loci. A SNP was deemed to have failed if fewer than 95% of DNA samples generated a genotype at the locus. To ensure quality of genotyping, a series of duplicate samples were genotyped and cases and controls were genotyped in the same batches.
Statistical methods
Statistical analyses were undertaken using R (http://www.r-project.org) and STATA Software (StataCorp LP, College Station, TX, USA). The adequacy of the case-control matching and possibility of differential genotyping of cases and controls were formally evaluated using Q-Q plots of test statistics. Genotypic frequencies in control subjects for each SNP were tested for departure from HWE using an exact test. To detect possible population stratification, we employed the genomic control approach (14) using all SNPs to estimate the stratification parameter and its associated 95% confidence interval (CI). The possibility of sex differences as a source of population substructure was evaluated by a genotype test for each SNP in male and female controls and the number of significant results at the 5% level was compared with the number expected by χ 2 test.
For each SNP, we tested the null hypothesis of no association with glioma using the Cochran-Armitage trend test calculated by logistic regression. As age and sex were not significantly associated with glioma risk within the data, we restricted adjustment to study centre.
We assumed an additive co-dominant model by fitting the number of rare alleles carried as an ordinal covariate. The likelihood ratio test for each SNP was therefore a 1 degree of freedom (df) test comparing a model that included terms for genotype and study with a model including only a term for study. The risk of glioma associated with each SNP was quantified by trend odds ratios (ORs) and their 95% CIs adjusted by logistic regression for study centre. To address multiple testing we calculated the false positive report probability (FPRP) for specific associations (15).
We assumed that the study had power to detect an OR of 1.3 and that the prior probability for association with glioma risk was 0.01 (16 SNP, single nucleotide polymorphism; MAF, minor allele frequency; FPRP, false positive report probability based on OR trend (assuming prior probability of 0.01 and power to detect an OR of 1.3); OR het , odds ratio of heterozygote versus common homozygote genotypes; OR hom , odds ratio of rare homozygote versus common homozygote genotypes; tag, haplotype tagging SNP; PHAST, log odds conservation score based on the multiple alignment of human, chimp, mouse, rat, dog, chicken, fugu, and zebrafish >15; ESE, exonic splicing enhancer; TFBS, transcription factor binding site;
UTR, untranslated region; nonsyn, nonsynonymous sequence variation; synon, synonymous sequence variation; NA, not applicable. 
